
BiomX Inc. (PHGE) Stock Forecast & Price Target
BiomX Inc. (PHGE) Analyst Ratings
Bulls say
BiomX is a promising biotech company that has a positive outlook due to its strong financial standing, with a cash balance of $8.1 million and a recent increase in share price through a reverse split. The company has made significant progress in addressing the FDA's concerns regarding its lead assets, BX211 and BX004, and received new feedback acknowledging the unmet need for treatments targeting P. aeruginosa infection in CF. Despite risks, the company's potential to attain higher market penetration and expand its valuation through additional indications and partnerships could lead to significant upside and achieving our target price of $26.
Bears say
BiomX is facing potential challenges with its FDA clinical trial approval for BX004 due to unresolved concerns surrounding the use of a third-party nebulizer device. Additionally, while the company has received positive FDA feedback for its fixed multi-phage cocktail, BX011, for the treatment of diabetic foot infections, they may face obstacles in reaching their projected market penetration and obtaining additional indications for its use. Finally, the FDA's recommended endpoints for the clinical trial of BX011 may require a large number of patients, which could be a potential barrier to achieving their target price.
This aggregate rating is based on analysts' research of BiomX Inc. and is not a guaranteed prediction by Public.com or investment advice.
BiomX Inc. (PHGE) Analyst Forecast & Price Prediction
Start investing in BiomX Inc. (PHGE)
Order type
Buy in
Order amount
Est. shares
0 shares